Peter Sabbatini

3.8k citations

29 papers · 3.1k indexed · 1 hit paper · h-index 20

Impact in

Oncology top 2%
- Cancer-related Molecular Pathways
Biotechnology top 1%
- Cancer Research and Treatments

Papers in

Oncology 14
- Cancer-related Molecular Pathways 10
- Chemokine receptors and signaling 4
Genetics 5
- Virus-based gene therapy research 7
- Chronic Lymphocytic Leukemia Research 5

Co-authors: Eileen White Lakshmi Rao Jeonghoon Han David M. Hockenbery S J Korsmeyer Frank McCormick William S.M. Wold L R Gooding
Journals: Blood (6 papers)Molecular and Cellular Biology (4 papers)Clinical Cancer Research (2 papers)Bioorganic & Medicinal Chemistry Letters (2 papers)Genes & Development (2 papers)
Partner nations: United States Netherlands Germany

In The Last Decade

Peter Sabbatini

28 papers receiving 3.0k citations

Hit Papers

align trajectories log scale

The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. 1992 · 567 citations

Peers

Countries citing papers authored by Peter Sabbatini

Since Specialization

Citations

This map shows the geographic impact of Peter Sabbatini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Sabbatini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Sabbatini more than expected).

Fields of papers citing papers by Peter Sabbatini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Sabbatini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Sabbatini. The network helps show where Peter Sabbatini may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Peter Sabbatini, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Sabbatini Line = papers co-authored together Peter Sabbatini links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	388MO Preliminary safety and efficacy of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in metastatic gastroesophageal carcinoma (mGEC) Annals of Oncology ·Shen Wang, Farshid Dayyani, Jeremy D. Kratz, Sungjae Kim, Chang Xu, Christoph M. Ahlers, Xin Liu, S E Salcudean, Peter Sabbatini, Amirullah Barki, Sang Kil Lee, Maheen Hasib, Geoffrey Y. Ku	2025	2
2	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma Clinical Cancer Research ·Irene M. Ghobrial, Chia‐Jen Liu, Robert Redd, Raymond P. Perez, Rachid Baz, Oksana Zavidij, Romanos Sklavenitis‐Pistofidis, Paul G. Richardson, Kenneth C. Anderson, Jacob P. Laubach, Patrick Henrick, Alexandra Savell, Kaitlen Reyes, Kalvis Hornburg, Stacey Chuma, Peter Sabbatini, Michael Robbins, Pamela S. Becker	2019	79
3	A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Blood ·Irene M. Ghobrial, Chia‐Jen Liu, Raymond P. Perez, Paul G. Richardson, Kenneth C. Anderson, Jacob P. Laubach, Patrick Henrick, Alexandra Savell, Kaitlen Reyes, Kalvis Hornburg, Stacey Chuma, Peter Sabbatini, Pamela S. Becker	2018	3
4	Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Blood ·Sylvia Chien, Daniel Cardona-Correa, Brent L. Wood, Elihu H. Estey, Frederick R. Appelbaum, Pina M. Cardarelli, Peter Sabbatini, Suresh G. Shelat, Lewis Cohen, Pamela S. Becker	2013	9
5	BMS-936564 (Anti-CXCR4 Antibody) Induces Specific Leukemia Cell Mobilization and Objective Clinical Responses In CLL Patients Treated Under a Phase I Clinical Trial Blood ·Manoj Kumar Kashyap, Mrs Misha Ansari, Ni Luh Putu Gopi Janawati, Tonny Saha, Michael Y. Choi, Michelle Kuhne, Lewis Cohen, Peter Sabbatini, Thomas J. Kipps, Pina M. Cardarelli, Januario E. Castro	2013	6
6	GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers Molecular Cancer Therapeutics ·Peter Sabbatini, Susan Korenchuk, Jason L. Rowand, Arthur Groy, Qi Liu, K Turjanmaa, Charity Atkins, Melissa Dumble, Jingsong Yang, Kelly K. Anderson, Ryan G. Kruger, Richard R. Gontarek, Kenneth R. Maksimchuk, Sapna Suravajjala, Luhrmann, J. Brad Shotwell, Joseph W. Wilson, Stanley D. Chamberlain, Sridhar K. Rabindran, Rakesh Kumar	2009	86
7	Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase Clinical Cancer Research ·Peter Sabbatini, Jason L. Rowand, Arthur Groy, Susan Korenchuk, Qi Liu, Charity Atkins, Melissa Dumble, Jingsong Yang, Kelly K. Anderson, Brian J. Wilson, Kyle A. Emmitte, Sridhar K. Rabindran, Rakesh Kumar	2009	62
8	Abstract #1740: Characterization of GSK1838705A, a small molecule inhibitor of the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase that delays growth of IGF-1R-dependent tumors and causes regression of ALK-dependent tumors in vivo Cancer Research ·Sridhar K. Rabindran, Peter Sabbatini, Susan Korenchuk, Arthur Groy, Jason L. Rowand, Qi Liu, K Turjanmaa, Charity Atkins, Melissa Dumble, Jingsong Yang, Kelly E. Fisher, Ryan G. Kruger, Kenneth R. Maksimchuk, Richard R. Gontarek, Sapna Suravajjala, Luhrmann, J. Brad Shotwell, Joseph W. Wilson, Stanley D. Chamberlain, Rakesh Kumar	2009	2
9	Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: Potent inhibitors of the IGF-1R receptor tyrosine kinase Bioorganic & Medicinal Chemistry Letters ·Stanley D. Chamberlain, Joseph W. Wilson, Felix Deanda, Samarjit Patnaik, Anikó M. Redman, Bin Yang, Lisa M. Shewchuk, Peter Sabbatini, M. Anthony Leesnitzer, Arthur Groy, Charity Atkins, Ruyu Yan, Anne M. Hassell, Huangshu Lei, Robert A. Mook, Ganesh S. Moorthy, Jason L. Rowand, Kirk L. Stevens, Rakesh Kumar, J. Brad Shotwell	2008	27
10	Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo Bioorganic & Medicinal Chemistry Letters ·Jeffrey R. Spencer, Martin Sendzik, Jason Oeh, Peter Sabbatini, Stacie A. Dalrymple, Catherine Magill, Hyunjin M. Kim, Penglie Zhang, Neil Squires, Katherine G. Moss, Juthamas Sukbuntherng, O M Brack, John Eksterowicz, Peter R. Young, Andrew G. Myers, Michael J. Green	2006	15
11	MDMX Inhibits the p300/CBP-Mediated Acetylation of p53 DNA and Cell Biology ·Peter Sabbatini, Frank McCormick	2002	42
12	Phosphoinositide 3-OH Kinase (PI3K) and PKB/Akt Delay the Onset of p53-mediated, Transcriptionally Dependent Apoptosis Journal of Biological Chemistry ·Peter Sabbatini, Frank McCormick	1999	121
13	The polyproline region of p53 is required to activate apoptosis but not growth arrest Oncogene ·Daitoku Sakamuro, Peter Sabbatini, Eileen White, George C. Prendergast	1997	244
14	Induction of Apoptosis by Human Nbk/Bik, a BH3-Containing Protein That Interacts with E1B 19K Molecular and Cellular Biology ·Jeonghoon Han, Peter Sabbatini, Eileen White	1996	165
15	Inhibition of apoptosis in human immunodeficiency virus-infected cells enhances virus production and facilitates persistent infection Journal of Virology ·Beth Ann Antoni, Peter Sabbatini, Arnold B. Rabson, Eileen White	1995	81
16	Modulation of p53-Mediated Transcriptional Repression and Apoptosis by the Adenovirus E1B 19K Protein Molecular and Cellular Biology ·Peter Sabbatini, Shiun‐Kwei Chiou, Lakshmi Rao, Eileen White	1995	163
17	Control of p53-dependent Apoptosis by E1B, Bcl-2, and Ha-ras Proteins Cold Spring Harbor Symposia on Quantitative Biology ·Eileen White, Shiun‐Kwei Chiou, Lakshmi Rao, Peter Sabbatini, Hung‐Jen Lin	1994	12
18	The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor alpha. Molecular and Cellular Biology ·Eileen White, Peter Sabbatini, Melissa Palacios Guillen, William S.M. Wold, Han Zhou, L R Gooding	1992	171
19	The 19-Kilodalton Adenovirus E1B Transforming Protein Inhibits Programmed Cell Death and Prevents Cytolysis by Tumor Necrosis Factor α Molecular and Cellular Biology ·Eileen White, Peter Sabbatini, Barabara Hamrick, William S.M. Wold, 路子降矢, L R Gooding	1992	315
20	Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins Journal of Virology ·Eileen White, Nancy C Canales-Navarrete, Peter Sabbatini, Amy Denton	1991	216

About Peter Sabbatini

Peter Sabbatini is a scholar working on Oncology, Genetics, Hematology, Biotechnology and Molecular Biology, having authored 29 papers that have together received 3.1k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (10 papers), Virus-based gene therapy research (7 papers), Chronic Lymphocytic Leukemia Research (5 papers), Multiple Myeloma Research and Treatments (5 papers), RNA Interference and Gene Delivery (4 papers), Chemokine receptors and signaling (4 papers), Growth Hormone and Insulin-like Growth Factors (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). The work is most often cited by research in Oncology (1.4k citations), Biotechnology (383 citations), Genetics (936 citations), Molecular Biology (2.0k citations) and Immunology (575 citations). Peter Sabbatini has collaborated with scholars based in United States, Netherlands and Germany. Frequent co-authors include Eileen White, Lakshmi Rao, Jeonghoon Han, David M. Hockenbery, S J Korsmeyer, Frank McCormick, William S.M. Wold, L R Gooding, George C. Prendergast and Daitoku Sakamuro. Their work appears in journals such as Blood, Molecular and Cellular Biology, Clinical Cancer Research, Bioorganic & Medicinal Chemistry Letters and Genes & Development.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact